Skip to main content
Premium Trial:

Request an Annual Quote

Amaxa to Oversee EU-Funded Effort to Develop Primary Cell Transfection Device

NEW YORK (GenomeWeb News) — Amaxa said today that it will coordinate an eight-member European alliance to develop devices for ultra-high-throughput transfection of primary cells.
The European Commission awarded the partnership more than €2.75 million ($3.7 million) in funding. The group will use Amaxa’s Nucleofector technology, the company said.
 
Amaxa said the development project, termed Modest-EU, is expected to last three years and includes Deutsches Rheumaforschungszentrum, RNAx, Protobios, Fotec, HTP High Tech Plastics, Dominion Pharmakine, and Prevas.

The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Sanction Violation Charges

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.